ERRFI1 Antibody

1. MIG-6 was a direct target of miR-374a, and the expression of MIG-6 was downregulated by the overexpression of miR-374a in HepG2 cells. PMID: 28734040
2. In Ishikawa human endometrial adenocarcinoma cell line MIG-6 negatively regulates the phosphorylation of STAT3 via direct protein interaction with STAT3. PMID: 28925396
3. The regulation mechanism of MIG6 and suggests potential implications for the therapeutic strategies of gefitinib resistance through inhibiting MEF2C in hepatic cancer cells. PMID: 29714661
4. Mig-6 deficiency promotes the development of Kras(G12D)-induced lung adenoma through reducing the cell apoptosis in Kras(G12D) mouse lungs partially by activating the ErbB4 pathway. PMID: 29191600
5. Cdc42 inhibition is required for Mig-6 suppression of cell migration induced by EGF PMID: 27341132
6. ectopic expression of Gene 33 triggers DNA damage response in an ATM serine/threonine kinase (ATM)-dependent fashion and through pathways dependent or not dependent on ABL proto-oncogene 1 non-receptor tyrosine kinase (c-Abl). PMID: 28842482
7. our data suggest that dormant cancer cells with a high MIG6 expression level might be one of the causes of EGFR-TKI resistance in EGFR mutant lung cancer cells. PMID: 27893711
8. Down-regulation of Mig-6 induces Cyclin D1 expression and activates the MAPK-ERK signaling pathway. Our study shows that the expression of Mig-6 protein is low in hepatocellular carcinoma, which predicts a poor prognosis. PMID: 28506767
9. PIPKIgammai5, NEDD4-1, and Mig6 form a novel molecular nexus that controls EGFR activation and downstream signaling. PMID: 27557663
10. Low MIG6 expression is associated with lung cancer. PMID: 26760771
11. Upregulation of mitogen-inducible gene 6 triggers antitumor effect and attenuates progesterone resistance in endometrial carcinoma cells PMID: 26450625
12. MIG6 down regulation may promote the migration and invasiveness of MEK inhibited mutant NRAS melanoma. PMID: 26967478
13. MIG6 is a potent tumor suppressor for mutant EGFR-driven lung tumor initiation and progression in mice and provides a possible mechanism by which mutant EGFR can partially circumvent this tumor suppressor in human lung adenocarcinoma. PMID: 25735773
14. Crystal structures of human EGFR-Mig6 complexes show how Mig6 rearranges after phosphorylation by EGFR to effectively irreversibly inhibit the same receptor that catalyzed its phosphorylation. PMID: 26280531
15. MIG-6 efficiently reduces cellular transformation driven by oncogenic BRAF by orchestrating a negative feedback circuit directed towards the EGFR. PMID: 26065894
16. study provides a new molecular mechanism to regulate EGFR signaling through modulation of MIG6 by DNAJB1 as a negative regulator. PMID: 26239118
17. Demonstrate that Mig-6 could reverse gefitinib resistance through inhibition of EGFR/ERK pathway in non-small cell lung cancer cell lines. PMID: 25400829
18. Mig-6 reduces pRb phosphorylation at Ser249/ Thr252 in both primary and B-Raf V600E oncogene expressing. PMID: 24815188
19. Mig-6 is a potential biomarker for evaluation of tumor prognosis of lung cancer. PMID: 24573418
20. Mechanistic model of EGFR endocytosis to determine the relative contributions of three parallel pathways of MIG6, ubiquitin ligase CBL and Sprouty2. PMID: 24445374
21. The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. PMID: 24830724
22. SPRY2 and MIG6 are important regulators of wild-type and mutant EGFR trafficking and points to an EGFR expression-independent function of SPRY2 in the regulation of ERK activity that may impact cellular sensitivity to EGFR inhibitors PMID: 23868981
23. The Mig-6 induces premature senescence via functioning in regulation of cellular senescence in normal diploid fibroblasts. PMID: 23746120
24. The EGF receptor (EGFR) regulator MIG6 and the apoptosis regulator BIM. PMID: 24425048
25. Data indicate that EGFR activity, which was more accurately predicted by the ratio of mitogen-inducible gene 6 (Mig6)/EGFR, highly correlated with erlotinib sensitivity in panels of cancer cell lines of different tissue origins. PMID: 23935914
26. ERRFI1 + 808 T/G polymorphism confers protective effect on diabetic nephropathy in a Korean population. PMID: 23324575
27. Mig6 functions as a molecular brake for beta-cell proliferation during glucocorticoid treatment in beta-cells, and thus, Mig6 may be a novel target for preventing glucocorticoid-induced impairments in functional beta-cell mass. PMID: 23384834
28. MIG-6 gene is differentially regulated in lung cancer and melanoma and can be epigenetically silenced by inhibitors of methylation and histone deacetylation. PMID: 22701735
29. results indicate that downregulated Mig-6 in NSCLC tissues may serve as a new marker that can predict the activation of EGFR signaling pathway PMID: 21739478
30. These results suggest that Chk1 phosphorylates Mig-6 on Ser 251, resulting in the inhibition of Mig-6, and that Chk1 acts as a positive regulator of EGF signalling. PMID: 22505024
31. Knockdown of PIM-1 but not of PIM-2 or PIM-3 also up regulates MIG6 expression, which identifies MIG6 as a PIM-1 regulated gene prostate cancer cells. PMID: 22193779
32. Treatment with AZD6244 reduced the expression of mitogen-inducible gene 6 (MIG6). PMID: 22082529
33. Mig6 plays a role in transmitting the effect of gefitinib to the downstream part of the EGFR signaling pathway. PMID: 21333004
34. Mig-6 knockdown in thyroid cancer cell lines resulted in epidermal growth factor receptor phosphorylation and diminished NF-kappaB activity, whereas Mig-6 overexpression had the opposite effects. PMID: 21190978
35. Mig-6 controls EGFR trafficking and suppresses gliomagenesis PMID: 20351267
36. MIG6 drives endocytosis and degradation of kinase-inactive EGFR PMID: 20421427
37. Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. PMID: 20044804
38. Full-length Mig-6, but not CRIB domain-deleted Mig-6 (DeltaMig-6) or uncleavable mutant of Mig-6 (Mig-6-S38A), induces transcriptional activation of nuclear factor of kappaB (NFkappaB). PMID: 12384522
39. induction by hypoxia PMID: 12387890
40. Gene 33 is a physiological feedback inhibitor of the EGFR, functioning to inhibit EGFR phosphorylation and all events induced by EGFR activation PMID: 15556944
41. C-terminal region of the Gene33 protein (ERBB receptor feedback inhibitor 1) regulates MEK-ERK pathway-directed Elk-dependent transcription. PMID: 15696545
42. RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents PMID: 15856022
43. MIG-6 is a tumor-suppressor gene associated with lung cancer PMID: 16819504
44. Review highlights important roles of Mig-6 in regulating stress response, maintaining homeostasis in tissues like joints or cardiac muscle, and functioning as a tumor suppressor. PMID: 17351343
45. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. PMID: 17599051
46. Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a approximately 25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain PMID: 18046415
47. new hypoxia-inducible and SOX9-regulated genes, Gdf10 and Chm-I. In addition, Mig6 and InhbA were induced by hypoxia, predominantly via HIF-2alpha PMID: 18077449
48. High mitogen inducible gene 6 expression in papillary thyroid cancer is associated with greater survival and MIG-6 expression correlates directly with EGFR expression. PMID: 19040996
49. Mig-6 is a critical regulator of the response of the endometrium to estrogen in regulating tissue homeostasis PMID: 19439667
50. cells accumulate MIG6 as an inherent negative regulator to suppress excess EGFR activity when basal EGFR kinase activity is considerably high. PMID: 19674104

显示更多

收起更多

HGNC: 18185

OMIM: 608069

KEGG: hsa:54206

STRING: 9606.ENSP00000366702

UniGene: Hs.605445